F
Folexen
Guest
Hi Aks20. Equol has an advantage in that it is naturally produced by some people, for instance about half of Japanese people are able to produce it. It's not exogenic in the way that 5AR inhibitors are.
There isn't evidence of bone density issues in Japan, in fact Japanese have about 40% fewer hip fractures than western people (Ross PD, et al. Am J Epidemiol 1991;133:801-9). This isn't direct proof, since Japanese people probably have other lifestyle factors that contribute to bone health.
There is no reason to believe that S-equol would be positively correlated with lower bone density.
We undertook a small evaluation of efficacy, the results are tabulated here: http://folexen.com/public/S-equol_eval_10mg_oral_BD_summary.zip
There have been some studies into the safety of S-equol, here is one that you might find interesting:
Yee S, et. al. Acute and subchronic toxicity and genotoxicity of SE5-OH, an equol-rich product produced by Lactococcus garvieae. Food Chem Toxicol 2008;46:2713-20.
http://www.ncbi.nlm.nih.gov/pubmed/18554770
There isn't evidence of bone density issues in Japan, in fact Japanese have about 40% fewer hip fractures than western people (Ross PD, et al. Am J Epidemiol 1991;133:801-9). This isn't direct proof, since Japanese people probably have other lifestyle factors that contribute to bone health.
There is no reason to believe that S-equol would be positively correlated with lower bone density.
We undertook a small evaluation of efficacy, the results are tabulated here: http://folexen.com/public/S-equol_eval_10mg_oral_BD_summary.zip
There have been some studies into the safety of S-equol, here is one that you might find interesting:
Yee S, et. al. Acute and subchronic toxicity and genotoxicity of SE5-OH, an equol-rich product produced by Lactococcus garvieae. Food Chem Toxicol 2008;46:2713-20.
http://www.ncbi.nlm.nih.gov/pubmed/18554770